Key Takeaway
Folic acid at doses of 0.5-5 mg daily reduces blood homocysteine by 25%, with an additional 7% reduction when combined with vitamin B12, establishing the foundational evidence for B-vitamin-based homocysteine lowering.
Summary
This landmark 1998 meta-analysis from the Homocysteine Lowering Trialists' Collaboration established the foundational dose-response data for folic acid supplementation and homocysteine reduction. Pooling data from 12 randomized controlled trials with 1,114 participants, it remains one of the most cited papers in methylation research.
The central finding was that folic acid reduces blood homocysteine by approximately 25% across a wide dose range (0.5-5 mg daily), with no meaningful additional benefit from higher doses. Adding vitamin B12 (mean dose 0.5 mg daily) provided a further 7% reduction, while vitamin B6 showed no significant additive effect. The magnitude of reduction depended heavily on baseline levels -- people with higher starting homocysteine and lower baseline folate saw the greatest benefit.
This study shaped supplementation guidelines for decades. The practical takeaway is that modest folic acid doses (around 0.5-1 mg) capture most of the homocysteine-lowering benefit, and combining with B12 adds meaningful value. The finding that B6 does not independently lower homocysteine (despite its role in the transsulfuration pathway) helped clarify the relative importance of different B vitamins in the methylation cycle.
Methods
- Meta-analysis of 12 randomized controlled trials (1,114 participants)
- Multivariate regression on log-transformed homocysteine values
- Adjusted for baseline homocysteine, folate, folic acid dose, B12/B6 co-supplementation
- Also adjusted for age, sex, and treatment duration
- Standardized results to typical Western baseline (homocysteine 12 umol/L, folate 12 nmol/L)
Key Results
- Folic acid reduced homocysteine by 25% (95% CI 23-28%) at typical Western baseline levels
- No significant dose-response difference across 0.5 mg, 1-3 mg, and >3 mg daily ranges
- Vitamin B12 (mean 0.5 mg/day) added a further 7% reduction (95% CI 3-10%)
- Vitamin B6 (mean 16.5 mg/day) had no significant additional effect
- Combined folic acid + B12 predicted to lower homocysteine from ~12 to 8-9 umol/L
- Greater reductions at higher pretreatment homocysteine (p < 0.001)
- Greater reductions at lower baseline folate (p < 0.001)
Figures
Figure 1
Figure 2
Figure 3
Limitations
- Longest treatment duration studied was only 12 weeks
- Did not assess effects on homocysteine after methionine loading
- Two completed trials (194 subjects) lacked available data for inclusion
- Only two trials lacked blinding (both with untreated controls)
- Could not determine whether homocysteine reduction actually reduces cardiovascular disease